TEL AVIV, Israel--(BUSINESS WIRE)--March 7, 2006--Compugen Ltd. (Nasdaq:CGEN) announced today that it is leading a consortium for the development of a platform to simulate the MAP-kinase pathway, a signaling pathway related to cancer which is already targeted by a number of cancer therapies and diagnostic tests.
